<- Go Home

VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.

Market Cap

$30.7M

Volume

220.2K

Cash and Equivalents

$199.4K

EBITDA

-$21.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$1.5M

Profit Margin

100.00%

52 Week High

$0.94

52 Week Low

$0.21

Dividend

N/A

Price / Book Value

-0.72

Price / Earnings

-0.99

Price / Tangible Book Value

-0.71

Enterprise Value

$40.5M

Enterprise Value / EBITDA

-1.89

Operating Income

-$22.7M

Return on Equity

78.71%

Return on Assets

-148.34

Cash and Short Term Investments

$199.4K

Debt

$11.3M

Equity

-$35.9M

Revenue

$1.5M

Unlevered FCF

-$31.1M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches